LitCovid-ArguminSci  

PubMed:32149773 JSONTXT 16 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T1 0-135 DRI_Background denotes Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial.
T2 136-321 DRI_Background denotes BACKGROUND: At the end of 2019, a novel coronavirus outbreak emerged in Wuhan, China, and its causative organism has been subsequently designated the 2019 novel coronavirus (2019-nCoV).
T3 322-441 DRI_Approach denotes The virus has since rapidly spread to all provinces and autonomous regions of China, and to countries outside of China.
T4 442-546 DRI_Background denotes Patients who become infected with 2019-nCoV may initially develop mild upper respiratory tract symptoms.
T5 547-663 DRI_Background denotes However, a significant fraction of these patients goes on to subsequently develop serious lower respiratory disease.
T6 664-869 DRI_Background denotes The effectiveness of adjunctive glucocorticoid therapy uses in the management of 2019-nCoV infected patients with severe lower respiratory tract infections is not clear, and warrants further investigation.
T7 870-964 DRI_Background denotes METHODS: The present study will be conducted as an open-labelled, randomised controlled trial.
T8 1036-1252 DRI_Background denotes Each eligible subject will be assigned to an intervention group (methylprednisolone via intravenous injection at a dose of 1-2mg/kg/day for 3 days) or a control group (no glucocorticoid use) randomly, at a 1:1 ratio.
T9 1253-1372 DRI_Approach denotes Subjects in both groups will be invited for 28 days of follow-up which will be scheduled at 4 consecutive visit points.
T10 1373-1439 DRI_Approach denotes We will use the clinical improvement rate as our primary endpoint.
T11 1440-1705 DRI_Outcome denotes Secondary endpoints include the timing of clinical improvement after intervention, duration of mechanical ventilation, duration of hospitalization, overall incidence of adverse events, as well as rate of adverse events at each visit, and mortality at 2 and 4 weeks.
T12 1706-1824 DRI_Challenge denotes DISCUSSION: The present coronavirus outbreak is the third serious global coronavirus outbreak in the past two decades.
T13 1825-1970 DRI_Background denotes Oral and parenteral glucocorticoids have been used in the management of severe respiratory symptoms in coronavirus-infected patients in the past.
T14 1971-2228 DRI_Challenge denotes However, there remains no definitive evidence in the literature for or against the utilization of systemic glucocorticoids in seriously ill patients with coronavirus-related severe respiratory disease, or indeed in other types of severe respiratory disease.
T15 2229-2417 DRI_Challenge denotes In this study, we hope to discover evidence either supporting or opposing the systemic therapeutic administration of glucocorticoids in severe coronavirus disease 2019 (COVID-19) patients.